Achiko AG: 2021 Annual General Meeting of Achiko AG: Shareholders adopt all proposals
Achiko AG / Key word(s): AGMEGM
26-May-2021 / 18:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
2021 Annual General Meeting of Achiko AG: Shareholders adopt all proposals
Zurich, 26 May 2021 - Achiko AG (SWX:ACHI, ISIN CH0522213468) ( Achiko or the Company ) held its Annual General Meeting today at 10:00 CEST in Zurich. Due to the Covid-19 pandemic, this Annual General Meeting was held without physical presence of the shareholders in accordance with art. 27 para. 1 letter b Covid-19-Ordinance 3. Shareholders exercised their shareholder rights through an independent proxy.
Share:
Production of first 1,000 AptameX test kits is concluded in Singapore (initial capacity to test 10,000 patients per day).
AptameX delivers sensitivity of 77% (95% CI: 75.94 - 79.24) at a high industry CT score of 28.3, which is comparable to current lateral flow rapid tests.
Moving to complete product registration in Indonesia and progressing to securing a CE mark in Europe with a view to approvals and sales in Q3 2021.
ZURICH, GERMANY / ACCESSWIRE / May 20, 2021 / Achiko AG (SWX:ACHI, ISIN CH0522213468) completed production of the first 1,000 AptameX test kits and has commenced shipment to Indonesia. The Company also announces favourable preliminary Covid-19 diagnostic testing results at a high CT score; even at low viral loads, AptameX proves to be highly sensitive.
May 20, 2021
Production of first 1,000 AptameX test kits is concluded in Singapore (initial capacity to test 10,000 patients per day).
AptameX delivers sensitivity of 77% (95% CI: 75.94 - 79.24) at a high industry CT score of 28.3, which is comparable to current lateral flow rapid tests.
Moving to complete product registration in Indonesia and progressing to securing a CE mark in Europe with a view to approvals and sales in Q3 2021.
ZURICH, SWITZERLAND - EQS Newswire - 20 May 2021 - Achiko AG (SWX:ACHI, ISIN CH0522213468) completed production of the first 1,000 AptameX test kits and has commenced shipment to Indonesia. The Company also announces favourable preliminary Covid-19 diagnostic testing results at a high CT score; even at low viral loads, AptameX proves to be highly sensitive.
Achiko AG / Key word(s): Preliminary Results
Achiko AG: Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, delivering 77% sensitivity at low viral loads
20-May-2021
The issuer is solely responsible for the content of this announcement. Achiko completes initial shipment of AptameX, its progressive Covid-19 diagnostic test, to Indonesia, delivering 77% sensitivity at low viral loads - Production of first 1,000 AptameX test kits is concluded in Singapore (initial capacity to test 10,000 patients per day). - AptameX delivers sensitivity of 77% (95% CI: 75.94 - 79.24) at a high industry CT score of 28.3, which is comparable to current lateral flow rapid tests.
Chief Operating Officer Chris Young to Retire
Focus on Product Development, Lowering Cost Profile and Improved Alignment of Resources
ZURICH, Switzerland, May 04, 2021 (GLOBE NEWSWIRE) Achiko AG (SWX:ACHI, ISIN CH0522213468) appoints Robert Rieder as Chief Financial Offer (“CFO”), replacing CFO ad interim Ruediger Petrikowski, who has done a phenomenal job driving results and accelerating the transformation since July 2020.
Mr. Rieder is a senior finance executive with over 20 years of experience in working with start-ups and high growth companies including several in the biotech and medtech space. Mr. Rieder has held influential roles in establishing and building finance teams, facilitating fundraising efforts and leading business and operations for domestic and international companies. He has extensive knowledge and experience in financial and cost accounting, budgeting, forecasting, financial planning and analysis within the United States, Europe and Asia.